Related Experiment Video
Updated: Dec 24, 2025
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Targeted Radionuclide Therapy of Prostate Cancer-From Basic Research to Clinical Perspectives
Malwina Czerwińska1, Aleksander Bilewicz2, Marcin Kruszewski1,3
1Centre for Radiobiology and Biological Dosimetry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.
Abstract:
Prostate cancer is the most commonly diagnosed malignancy in men and the second leading cause of cancer-related deaths in Western civilization. Although localized prostate cancer can be treated effectively in different ways, almost all patients progress to the incurable metastatic castration-resistant prostate cancer. Due to the significant mortality and morbidity rate associated with the progression of this disease, there is an urgent need for new and targeted treatments. In this review, we summarize the recent advances in research on identification of prostate tissue-specific antigens for targeted therapy, generation of highly specific and selective molecules targeting these antigens, availability of therapeutic radionuclides for widespread medical applications, and recent achievements in the development of new-generation small-molecule inhibitors and antibody-based strategies for targeted prostate cancer therapy with alpha-, beta-, and Auger electron-emitting radionuclides.
Insights
New targeted therapies are emerging for metastatic castration-resistant prostate cancer. Research focuses on prostate-specific antigens and novel molecular strategies using therapeutic radionuclides for improved treatment outcomes.
Area of Science:
- Oncology
- Radiochemistry
- Molecular Biology
Background:
- Prostate cancer is a leading cause of cancer death in men.
- Localized prostate cancer is treatable, but most patients develop incurable metastatic castration-resistant prostate cancer.
- There is a critical need for novel therapeutic strategies to combat advanced prostate cancer.
Purpose of the Study:
- To review recent advances in targeted prostate cancer therapy.
- To highlight the development of specific molecules targeting prostate antigens.
- To discuss the application of radionuclides in novel therapeutic approaches.
Main Methods:
- Identification of prostate tissue-specific antigens.
- Generation of specific targeting molecules (small-molecule inhibitors, antibodies).
- Utilizing alpha-, beta-, and Auger electron-emitting radionuclides for targeted therapy.
Main Results:
- Advances in identifying and targeting prostate-specific antigens.
- Development of new-generation small-molecule inhibitors and antibody-based strategies.
- Increased availability and application of therapeutic radionuclides.
Conclusions:
- Targeted therapies show promise for treating metastatic castration-resistant prostate cancer.
- Combining antigen targeting with radionuclide therapy offers a potent strategy.
- Continued research is crucial for developing effective treatments for advanced prostate cancer.
